A leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, WuXi Biologics and Aravive Biologics, have announced plans to expand their biologics manufacturing collaboration.

This extension is based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive's lead drug candidate, AVB-S6-500 (previously referred to as Aravive-S6). The decision follows the successful filing of a US Investigational New Drug application (IND) for AVB-S6-500, a novel GAS6-AXL pathway inhibitor which Aravive is developing for the treatment of cancer and non-malignant fibrotic conditions.

Last year, WuXi Biologics' cGMP facility in Wuxi city became the first China-based manufacturing facility to complete a US Food and Drug Administration (US FDA) Pre-License Inspection (PLI) for any biologics drug under FDA review, which paved the way for biologics commercial manufacturing.